Tarsus Pharmaceuticals, Inc. TARS Number of Vested and Expected to Vest Options
Number of Vested and Expected to Vest Options at other companies
Other financials
Where this comes from
Reported directly by Tarsus Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue.
The official record: Tarsus Pharmaceuticals, Inc.’s 10-K, filed February 23, 2026, on SEC EDGAR. View the filing →
Ask your AI about Tarsus Pharmaceuticals, Inc.'s number of vested and expected to vest options.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Tarsus Pharmaceuticals, Inc.'s number of vested and expected to vest options?
- Tarsus Pharmaceuticals, Inc. (TARS) reported number of vested and expected to vest options of $248.05M in Q4 2025.
- How has Tarsus Pharmaceuticals, Inc.'s number of vested and expected to vest options changed year-over-year?
- Tarsus Pharmaceuticals, Inc.'s number of vested and expected to vest options increased by 88.8% year-over-year, from $131.36M to $248.05M.
- What is the long-term trend for Tarsus Pharmaceuticals, Inc.'s number of vested and expected to vest options?
- Over 5 years (2020 to 2025), Tarsus Pharmaceuticals, Inc.'s number of vested and expected to vest options has grown at a 71.0% compound annual growth rate (CAGR), from $16.99M to $248.05M.
- What does number of vested and expected to vest options mean?
- This metric represents the total number of share-based payment options that have met vesting requirements or are reasonably expected to vest based on current service conditions. It provides insight into the potential dilution of shareholder equity and the long-term incentive alignment for employees and management.